Trial Profile

Tacrolimus monotherapy in immunologically low-risk kidney transplant recipients: a pilot randomized-controlled study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tacrolimus (Primary) ; Mycophenolate mofetil
Indications Renal transplant rejection
Focus Therapeutic Use

Most Recent Events

08 Jun 2022 Results of an analysis assessed the effect of mycophenolate mofetil (MMF) on SARS-CoV-2 vaccination response in kidney transplant recipients using the standard immunosuppressive regimen of tacrolimus (TAC) and MMF presented at the 2022 American Transplant Congress
08 Jun 2022 Status changed from recruiting to completed as per results presented at the 2022 American Transplant Congress
21 Sep 2017 Planned number of patients changed from 100 to 120.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com